Download Files:
Products Details
Product Description
– Encequidar (HM30181) mesylate hydrochloride is a potent and selective inhibitor of P-glycoprotein (MDR1). Encequidar mesylate hydrochloride improves anti-tumor efficacy of Paclitaxel (HY-B0015) in mouse tumor models[1][2][3].
Web ID
– HY-13646C
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C39H42N6O11S
References
– [1]McCaw ZR, et al. Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. J Clin Oncol. 2023 Feb 20;41(6):1323.|[2]Kim TE, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol. 2014 Sep;78(3):556-64.|[3]Bauer F, et al. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol. 2012 Dec 5;696(1-3):18-27.
CAS Number
– 2097125-58-9
Molecular Weight
– 802.85
SMILES
– O=C1C=C(C(NC2=CC(OC)=C(C=C2C3=NN(C4=CC=C(CCN5CC6=CC(OC)=C(C=C6CC5)OC)C=C4)N=N3)OC)=O)OC7=C1C=CC=C7.O=S(O)(C)=O.O
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– P-glycoprotein
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
